Singapore- and New York-headquartered health tech startup Holmusk secured $45.7 million this week from investors in Series B financing.
The round comprises $20 million in fresh equity funding from lead investor Veradigm, a Nasdaq-listed health tech firm formerly known as Allscripts Healthcare Solutions, and allotment of Series B1 shares upon conversion of notes to investors, including Heritas Capital, Optum Ventures, Health Catalyst Capital and Novartis.
